Compare Entegris Inc (ENTG) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs IDEXX Laboratories, Inc. — how do they compare? Entegris Inc trades at $133.17 (market cap $21.12B), while IDEXX Laboratories, Inc. trades at $574.92 (market cap $43.94B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.1× Entegris Inc's market cap, and Entegris Inc pays a 0.29% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| ENTG | IDXX | |
|---|---|---|
Market Cap | $21.12B | $43.94B |
Sector | Technology | Health |
52-Week High | $184.00 | $766.68 |
52-Week Low | $68.80 | $514.61 |
Enterprise Value | $24.44B | $44.84B |
Dividend Yield | 0.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $134.15, down 4.61% today, with technical indicators showing bearish momentum as the stock approaches key support at $133. The company maintains solid fundamentals with Q1 2026 earnings beating estimates at $0.86 per share and strong analyst consensus of 65% buy ratings. Recent developments include a $0.10 dividend declaration and new CFO appointment, while semiconductor industry tailwinds from AI-driven demand provide growth catalysts.
ENTG presents a compelling opportunity with 25% upside to the $178.40 consensus price target, supported by improving cash flow trends and semiconductor sector growth. However, elevated valuation multiples (P/E 80.17) and technical bearish signals warrant caution amid recent price volatility and competitive pressures in the semiconductor materials space.
IDXX trades at $572.38, up 5.86% over 24 hours, with a neutral technical signal and strong fundamentals. The company reported Q1 2026 EPS of $3.47, beating estimates, and maintains robust profitability with a 24.63% net margin. Revenue growth accelerated to $4.3 billion in 2025, supported by innovation in veterinary diagnostics and AI integration. Cash flow from operations remains healthy at $1.18 billion, though net cash flow was negative $108 million due to financing activities.
Outlook is positive given consistent earnings beats and analyst consensus leaning buy (59% of ratings). Key risks include high valuation multiples (P/E 40.99) and competitive pressures in medical devices. The stock's proximity to its 52-week high suggests momentum but warrants caution on pullbacks. Institutional sentiment is bolstered by product expansions like taeniid tapeworm detection and SDMA integration for kidney disease screening.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
